Two Sigma Investments’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Two Sigma Investments’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-9,000	Closed	-$739K	–	4834
2025 Q4	$739K	Buy	+9,000	New	+$696K	﹤0.01%	3107
2025 Q2	–	Sell	-3,900	Closed	-$247K	–	3441
2025 Q1	$247K	Sell	3,900 -200	-5%	-$13.5K	﹤0.01%	2790
2024 Q4	$273K	Sell	4,100 -2,100	-34%	-$145K	﹤0.01%	2765
2024 Q3	$433K	Buy	+6,200	New	+$429K	﹤0.01%	2534
2024 Q2	–	Sell	-5,000	Closed	-$324K	–	3248
2024 Q1	$324K	Buy	+5,000	New	+$325K	﹤0.01%	2527

Other funds holding PBE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

GKWIM

Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return

YIA

YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return

Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return

Two Sigma Investments's PBE Position: Q1 2026 in Review

Two Sigma Investments sold out of Invesco Biotechnology & Genome ETF (PBE) in Q1 2026, closing a stake of 9,000 shares — an estimated $739K sold.

Two Sigma Investments first reported a position in PBE in Q1 2024 and held it in 5 quarters. The position peaked at $739K in Q4 2025. 100 funds tracked by Wall St. Rank hold PBE as of Q1 2026.

Two Sigma Investments reported no remaining Invesco Biotechnology & Genome ETF position as of Q1 2026 after selling out during the quarter.
Two Sigma Investments sold 9,000 Invesco Biotechnology & Genome ETF shares in Q1 2026, an estimated $739K.
Two Sigma Investments first reported a position in Invesco Biotechnology & Genome ETF in Q1 2024 and held it in 5 quarters.
Two Sigma Investments's Invesco Biotechnology & Genome ETF position peaked at $739K in Q4 2025.
100 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.